Hepatic S1P Deficiency Reduces Atheroma Formation in LDLR-/- Mice (P5.227)

Conclusion: Hepatic S1P is a physiological modulator of plasma lipid metabolism through its regulation of VLDL secretion, especially when LDLR function is compromised. Utilizing genetic models, our data demonstrate the protective effect of hepatic S1P inhibition for reducing atheroma formation. Thus, S1P inhibitors could be potentially used to treat atherosclerosis and prevent stroke.Disclosure: Dr. Jin has nothing to disclose. Dr. Basu has nothing to disclose.

Source: Neurology - April 3, 2016 Category: Neurology Authors: Jin, W., Basu, D. Tags: Cerebrovascular Disease: Animal Models and In Vitro Models Source Type: research